Topas Therapeutics is a clinical-stage biotechnology company with a mission to deliver novel, disease-modifying treatments for autoimmune and inflammatory diseases. At Topas we are developing a proprietary platform of antigen-specific nanoparticle conjugates, called TPCs (Topas Particle Conjugates) uniquely positioned to address major unmet need in T-cell mediated diseases in a targeted manner. TPCs are uniquely engineered to restore and promote immune tolerance by targeting liver sinusoidal endothelial cells (LSECs) and harnessing antigen-specific immune tolerance mechanisms of the liver. Our technology has delivered to date two clinical candidates: TPM203 (Phase 1 pemphigus vulgaris) and TPM 502 (Phase 2 celiac disease).
Location: Germany, Hamburg
Employees: 11-50
Total raised: $63.15M
Founded date: 2013
Investors 3
| Date | Name | Website |
| - | Vesalius B... | vesaliusbi... |
| 16.06.2022 | GIMV | gimv.com |
| 15.07.2025 | Epidarex C... | epidarex.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 29.07.2021 | Series B | $47.49M | - |
| 23.03.2016 | Series A | $15.66M | - |
Mentions in press and media 13
| Date | Title | Description |
| 15.10.2024 | Topas Therapeutics Announces Positive Topline Results from Phase 2a Trial | - |
| 29.07.2021 | Topas Therapeutics GmbH : Extends Series B, Raising Total of ?40 Million (~$ 48 Million) in this Round | DGAP-News: Topas Therapeutics GmbH / Key word(s): Financing Topas Therapeutics Extends Series B, Raising Total of ?40 Million (~$ 48 Million) in this Round 29.07.2021 / 09:00 The issuer is solely responsible for the content of this announce... |
| 29.07.2021 | Evotec : spin-off Topas Therapeutics extends Series B, raising total of 40 m (~ $ 48 m) in this Round | Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases Initial clinical data for lead program, TPM20... |
| 29.07.2021 | PRESS RELEASE : Topas Therapeutics Extends Series B, Raising Total of EUR40 Million (USD 48 Million) in this Round | DGAP-News: Topas Therapeutics GmbH / Key word(s): Financing Topas Therapeutics Extends Series B, Raising Total of EUR40 Million (USD 48 Million) in this Round 2021-07-29 / 09:00 The issuer is solely responsible for the content of this annou... |
| 29.07.2021 | Evotec : spin-off Topas Therapeutics extends Series B, raising total of 40 Million (~$48 Million) in this Round | Evotec spin-off Topas Therapeutics extends Series B, raising total of €40 Million (~$48 Million) in this Round Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring i... |
| 29.07.2021 | Evotec : spin-off Topas Therapeutics extends Series B, raising total of 40 m (~$ 48 m) in this round | Evotec spin-off Topas Therapeutics extends Series B, raising total of € 40 m (~$ 48 m) in this round Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tole... |
| 29.07.2021 | Gimv : Topas Therapeutics announces and extended Series B round with an additional 18 million (± $ 22 million) | Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases Initial clinical data for lead program, TPM20... |
| 27.07.2021 | Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round | - |
| 27.07.2021 | Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) | - |
| 19.10.2020 | Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing | - |
Show more